{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=moxifloxacin&page=3",
    "query": {
      "intervention": "moxifloxacin",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 308,
    "total_pages": 31,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=moxifloxacin&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=moxifloxacin&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T13:46:18.073Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01069900",
      "title": "Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Intraabdominal Infections"
      ],
      "interventions": [
        {
          "name": "Moxifloxacin (Avelox, BAY12-8039)",
          "type": "DRUG"
        },
        {
          "name": "Ertapenem",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin/Clavulanate",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin placebo",
          "type": "DRUG"
        },
        {
          "name": "Ertapenem placebo",
          "type": "DRUG"
        },
        {
          "name": "Amoxicillin/Clavulanate placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Months to 17 Years"
      },
      "enrollment_count": 458,
      "start_date": "2010-07-21",
      "completion_date": "2015-01-21",
      "has_results": true,
      "last_update_posted_date": "2018-03-20",
      "last_synced_at": "2026-10-01T13:46:18.073Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Springfield, Massachusetts",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Springfield",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01069900"
    },
    {
      "nct_id": "NCT00464438",
      "title": "A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bacterial Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "gatifloxacin",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin 0.5% eye drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "31 Days",
        "sex": "ALL",
        "summary": "Up to 31 Days"
      },
      "enrollment_count": 171,
      "start_date": "2007-06",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2011-09-21",
      "last_synced_at": "2026-10-01T13:46:18.073Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00464438"
    },
    {
      "nct_id": "NCT02222324",
      "title": "A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "E2609",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2014-08",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-11-03",
      "last_synced_at": "2026-10-01T13:46:18.073Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02222324"
    },
    {
      "nct_id": "NCT07212803",
      "title": "Effects of Energy Drinks on Cardiovascular Endpoints",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Safety After Oral Intake"
      ],
      "interventions": [
        {
          "name": "Energy Drink A + Placebo Capsule",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Drink + Moxifloxacin Capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo Drink + Caffeine Capsule",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo Drink + Placebo Capsule",
          "type": "OTHER"
        },
        {
          "name": "Energy Drink B",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Control Product + Taurine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Control Product + Caffeine + Taurine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Lower Dose Energy Drink A",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of the Pacific",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 3,
      "start_date": "2025-11-01",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-10-01T13:46:18.073Z",
      "location_count": 1,
      "location_summary": "Stockton, California",
      "locations": [
        {
          "city": "Stockton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07212803"
    },
    {
      "nct_id": "NCT01049022",
      "title": "Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections"
      ],
      "interventions": [
        {
          "name": "Moxifloxacin (Avelox, BAY12-8039)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "3 Months to 14 Years"
      },
      "enrollment_count": 31,
      "start_date": "2010-05",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2015-07-22",
      "last_synced_at": "2026-10-01T13:46:18.073Z",
      "location_count": 11,
      "location_summary": "Little Rock, Arkansas • Orange, California • San Diego, California + 8 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01049022"
    },
    {
      "nct_id": "NCT04563845",
      "title": "Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "GSK3640254",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 50,
      "start_date": "2020-11-09",
      "completion_date": "2021-10-30",
      "has_results": true,
      "last_update_posted_date": "2023-12-06",
      "last_synced_at": "2026-10-01T13:46:18.073Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04563845"
    },
    {
      "nct_id": "NCT03155893",
      "title": "A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ODV Placebo (Matching 25 mg ODV)",
          "type": "DRUG"
        },
        {
          "name": "ODV Placebo (Matching 200 mg ODV)",
          "type": "DRUG"
        },
        {
          "name": "ODV Placebo (Matching 125 mg ODV)",
          "type": "DRUG"
        },
        {
          "name": "ODV Placebo (Matching 100 mg ODV)",
          "type": "DRUG"
        },
        {
          "name": "SMV Placebo (Matching 150 mg SMV)",
          "type": "DRUG"
        },
        {
          "name": "AL-335 Placebo (matching 1200 mg AL-335)",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin Placebo (matching 400 mg moxifloxacin)",
          "type": "DRUG"
        },
        {
          "name": "ODV 25 mg",
          "type": "DRUG"
        },
        {
          "name": "ODV 200 mg",
          "type": "DRUG"
        },
        {
          "name": "ODV 125 mg",
          "type": "DRUG"
        },
        {
          "name": "ODV 100 mg",
          "type": "DRUG"
        },
        {
          "name": "SMV 150 mg",
          "type": "DRUG"
        },
        {
          "name": "AL-335 1200 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 59,
      "start_date": "2017-05-12",
      "completion_date": "2017-10-27",
      "has_results": false,
      "last_update_posted_date": "2017-11-14",
      "last_synced_at": "2026-10-01T13:46:18.073Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03155893"
    },
    {
      "nct_id": "NCT00979316",
      "title": "Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "BMS-708163",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 62,
      "start_date": "2009-09",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2011-01-07",
      "last_synced_at": "2026-10-01T13:46:18.073Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00979316"
    },
    {
      "nct_id": "NCT01839279",
      "title": "A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spasticity"
      ],
      "interventions": [
        {
          "name": "Tizanidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acorda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 136,
      "start_date": "2013-04",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2021-03-23",
      "last_synced_at": "2026-10-01T13:46:18.073Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01839279"
    },
    {
      "nct_id": "NCT00492024",
      "title": "BAY12-8039: 5 Days for Sinusitis vs Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sinusitis"
      ],
      "interventions": [
        {
          "name": "Moxifloxacin (Avelox, BAY12-8039)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 374,
      "start_date": "2005-01",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2013-11-26",
      "last_synced_at": "2026-10-01T13:46:18.073Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Northport, Alabama • Jonesboro, Arkansas + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00492024"
    }
  ]
}